Research programme: obesity therapeutics - Unigene

Drug Profile

Research programme: obesity therapeutics - Unigene

Alternative Names: Anorexigenic peptide - Unigene; UGL 269; UGP-281

Latest Information Update: 24 May 2012

Price : $50

At a glance

  • Originator Unigene Laboratories
  • Class Peptides
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 22 May 2012 Pharmacodynamics data from preclinical trials released by Unigene
  • 28 Jun 2011 Final pharmacodynamics data from preclinical trials in Obesity presented at the 71st Annual Scientific Sessions of the American Diabetes Assocation (ADA-2011)
  • 12 Feb 2011 Unigene accelerates development of UGP 281 for obesity and is planning to file an IND in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top